These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 34917263)

  • 21. Cancer/testis antigens (CTAs) expression in resected lung cancer.
    Jin S; Cao S; Li J; Meng Q; Wang C; Yao L; Lang Y; Cao J; Shen J; Pan B; Hu J; Yu Y
    Onco Targets Ther; 2018; 11():4491-4499. PubMed ID: 30122941
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers.
    Salmaninejad A; Zamani MR; Pourvahedi M; Golchehre Z; Hosseini Bereshneh A; Rezaei N
    Immunol Invest; 2016 Oct; 45(7):619-40. PubMed ID: 27603913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumor activity of human γδ T cells transducted with CD8 and with T-cell receptors of tumor-specific cytotoxic T lymphocytes.
    Hanagiri T; Shigematsu Y; Kuroda K; Baba T; Shiota H; Ichiki Y; Nagata Y; Yasuda M; So T; Takenoyama M; Tanaka F
    Cancer Sci; 2012 Aug; 103(8):1414-9. PubMed ID: 22621620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of autoantibodies against cancer-testis antigens in non-small cell lung cancer.
    Djureinovic D; Dodig-Crnković T; Hellström C; Holgersson G; Bergqvist M; Mattsson JSM; Pontén F; Ståhle E; Schwenk JM; Micke P
    Lung Cancer; 2018 Nov; 125():157-163. PubMed ID: 30429015
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of GAGE, NY-ESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma.
    Gjerstorff MF; Pøhl M; Olsen KE; Ditzel HJ
    BMC Cancer; 2013 Oct; 13():466. PubMed ID: 24103781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Establishment of cancer/testis antigen profiling based on clinicopathological characteristics in resected pathological stage III non-small cell lung cancer.
    Jin S; Cao S; Grigorev A; Li J; Meng Q; Wang C; Feng M; Hu J; Jiang F; Yu Y
    Cancer Manag Res; 2018; 10():2031-2046. PubMed ID: 30038519
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of Novel
    Ou SI; Xiu J; Nagasaka M; Xia B; Zhang SS; Zhang Q; Swensen JJ; Spetzler D; Korn WM; Zhu VW; Liu SV
    JTO Clin Res Rep; 2021 Feb; 2(2):100132. PubMed ID: 34589990
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative molecular profiling of pancreatic ductal adenocarcinoma of the head versus body and tail.
    Abdelrahim M; Esmail A; Kasi A; Esnaola NF; Xiu J; Baca Y; Weinberg BA
    NPJ Precis Oncol; 2024 Apr; 8(1):85. PubMed ID: 38582894
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
    Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
    Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
    Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.
    Krieger T; Pearson I; Bell J; Doherty J; Robbins P
    Diagn Pathol; 2020 Jan; 15(1):6. PubMed ID: 32000815
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
    Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
    Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
    Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
    Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. miRNAs in lung cancer. A systematic review identifies predictive and prognostic miRNA candidates for precision medicine in lung cancer.
    Zhong S; Golpon H; Zardo P; Borlak J
    Transl Res; 2021 Apr; 230():164-196. PubMed ID: 33253979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of New York esophageal squamous cell carcinoma 1 and its association with Foxp3 and indoleamine-2,3-dioxygenase in microenvironment of nonsmall cell lung cancer.
    Wang H; Xia Y; Yu J; Guan H; Wu Z; Ban D; Wang M
    HLA; 2019 Jul; 94(1):39-48. PubMed ID: 30953385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrating Imaging, Histologic, and Genetic Features to Predict Tumor Mutation Burden of Non-Small-Cell Lung Cancer.
    Zhang N; Wu J; Yu J; Zhu H; Yang M; Li R
    Clin Lung Cancer; 2020 May; 21(3):e151-e163. PubMed ID: 31734072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
    Sabari JK; Leonardi GC; Shu CA; Umeton R; Montecalvo J; Ni A; Chen R; Dienstag J; Mrad C; Bergagnini I; Lai WV; Offin M; Arbour KC; Plodkowski AJ; Halpenny DF; Paik PK; Li BT; Riely GJ; Kris MG; Rudin CM; Sholl LM; Nishino M; Hellmann MD; Rekhtman N; Awad MM; Drilon A
    Ann Oncol; 2018 Oct; 29(10):2085-2091. PubMed ID: 30165371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer.
    Chen Y; Liu Q; Chen Z; Wang Y; Yang W; Hu Y; Han W; Zeng H; Ma H; Dai J; Zhang H
    J Exp Clin Cancer Res; 2019 May; 38(1):193. PubMed ID: 31088500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker.
    He B; Dong D; She Y; Zhou C; Fang M; Zhu Y; Zhang H; Huang Z; Jiang T; Tian J; Chen C
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32636239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.